Cybin receives institutional review board approval for its phase 1/2a clinical trial evaluating cyb003 for the treatment of major depressive disorder

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (cybin or the “company”), a biopharmaceutical company focused on progressing “psychedelics to therapeuticstm”, today announced that it has received institutional review board (“irb”) approval to begin the first-in-human phase 1/2a clinical trial evaluating cyb003, its proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“mdd”). “irb approval of our trial protocol is a significant regulatory
CYBN Ratings Summary
CYBN Quant Ranking